Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Corp.

Latest From Boston Scientific Corp.

Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific

Starts & Stops is a regular feature highlighting Medtech Insight's monthly picks of noteworthy clinical trial announcements, initiations, completions, and suspensions. The list for December is headlined by announcements on Edwards' transcatheter valve technologies. Meanwhile, MValve, a company Boston Scientific has invested heavily in, is not going forward with a planned trial of its MValve dock device with Boston Scientific's Lotus valve.

Clinical Trials Starts & Stops

MRI And Cardiac-Rhythm Devices: A Match Made In Medicare

A proposed coverage policy from the US Centers of Medicare and Medicaid Services would not only cover magnetic resonance imaging for patients with an implanted cardiac rhythm management device with an FDA-approved indication for MRI-compatibility, but will also cover MRI in patients with devices without that FDA labeling in certain circumstances.

United States Clinical Trials

JPM2018: $15bn Market Opp Awaits Boston Scientific, Forecasts Mahoney

Boston Scientific CEO and chairman Mike Mahoney provided a positive preliminary Q4 earnings outlook during his presentation at the JP Morgan HealthCare Conference on Jan. 9, and outlined plans for the medical device giant's growth for 2018 and beyond, including a $15bn market opportunity between 2018 and 2021.

Sales & Earnings Companies

Medtech Supporter Sen. Orrin Hatch To Retire At Year's End

The medtech industry will lose a champion in Congress when Senate Finance Panel Chair Orrin Hatch, R-Utah, retires at the end of the 2018 congressional session. Author of the Americans with Disabilities Act and the Children's Health Insurance Program law, Hatch has been a perennial supporter of device-tax repeal, introduced market-based pricing for lab test reimbursements, and sponsored deep cuts in taxes for corporations in tax reform legislation signed into law just last month. Might former Massachusetts governor and failed 2008 US presidential candidate Mitt Romney run for the soon-to-be vacated seat?

Leadership Policy
See All

Company Information